|
SurroMed, Inc. today announced the promotion of Christopher Becker, Ph.D., to the position of Vice President Chemistry and of William Leschensky, M.D., J.D. to the position of Vice President Intellectual Property.
Dr. Becker joined SurroMed in 2001 as Director of Chemistry. Prior to joining SurroMed, Dr. Becker conducted his postdoctoral work at MIT in chemistry and physics and was a staff scientist at SRI International and then a senior director of proteomic technology at Thermo Electron Corporation. Dr. Becker received his Ph.D. in chemistry at UC Berkeley.
“Chris and his team have developed a premier platform for biomarker discovery using a mass spectrometry-based bioanalysis for differential quantification of proteins, peptides and metabolites in biological samples,” said Howard Schulman, Ph.D., SurroMed’s Vice President of Research and Development. “This platform is critical to SurroMed’s internal efforts to discover diagnostic biomarkers for a range of diseases and to build value for our collaborators’ and customers’ drug development programs.”
Dr. Leschensky joined SurroMed in 2000 as Director of Intellectual Property and has served as Associate General Counsel. Prior to joining SurroMed, Dr. Leschensky was an associate at the law firm of Fish & Neave. Dr. Leschensky received his M.D. from the University of Illinois and his law degree from Harvard Law School.
“Bill has helped us create significant value as the leader of our intellectual property efforts at SurroMed and Nanoplex Technologies, our nanotechnology subsidiary, said Gordon Ringold, Ph.D., SurroMed’s Chief Executive Officer and Chairman. “Through his efforts, we have received, and expect to continue to receive in the future, a wide range of patents that should provide significant future value to SurroMed and Nanoplex.”
About SurroMed, Inc.
SurroMed is pioneering biomarker enabled drug discovery and development. The company focuses on discovering and applying biomarkers to improve the drug discovery and development process and enable the precise diagnosis and personalized treatment of disease. SurroMed's research process yields biological markers and information that enable accelerated, cost-efficient discovery and development of new therapeutic products, as well as development of diagnostic tests for early disease detection, disease staging, patient stratification, and guiding and monitoring therapy.
Contacts:
SurroMed, Inc.
August J. Moretti
CFO and General Counsel
(650) 230-1564
email: [email protected]
Euro RSCG Life NRP
Jeannine Medeiros
Vice President
Tel: (415) 901-3709
email: [email protected]
|
